Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease

G D'Haens, S Vermeire, G Lambrecht, F Baert, P Bossuyt, B Pariente, A Buisson, Y Bouhnik, J Filippi, C.J. van der Woude, P Van Hootegem, J Moreau, E Louis, D Franchimont, M Vos, F Mana, L Peyrin-Biroulet, H Brixi, M Allez, P CaenepeelA Aubourg, B Oldenburg, M Pierik, A van Gils, S Chevret, D Laharie, Getaid

Research output: Contribution to journalArticleAcademicpeer-review

233 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)1343-+
Issue number5
Publication statusPublished - 2018

Research programs

  • EMC MM-04-20-01

Cite this